MedPath

MindMed to lead first LSD Phase 3 trials for anxiety - Drug Discovery and Development

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

MindBio's Phase 2B Trials of MB22001 Microdosing Show Positive Safety Profile

MindBio's Phase 2B trials of MB22001 for major depressive disorder and advanced-stage cancer have passed a mandatory safety audit.
The independent review found no serious adverse events, allowing the trials to proceed as planned toward completion in late 2025.

MindMed's MM120 Shows Promise in Phase 2b Trial for Generalized Anxiety Disorder

MindMed's MM120, a lysergide d-tartrate (LSD) formulation, demonstrates rapid and durable improvement in patients with generalized anxiety disorder (GAD) after a single dose in Phase 2b trial.
The Phase 2b study results have prompted the initiation of Phase 3 trials, incorporating randomized, double-blind, placebo-controlled designs to validate the efficacy and safety of MM120.

MindMed Initiates Phase III Trial of MM120 (LSD) for Generalized Anxiety Disorder

MindMed has launched a Phase III clinical trial for MM120, an oral tablet formulation of LSD, for treating generalized anxiety disorder (GAD).
The trial will involve 200 participants across 20 U.S. sites, comparing MM120 to a placebo over a 12-week period, followed by a 40-week open-label extension.

MindMed Advances MM120 for GAD with Phase 3 Trials Underway

MindMed has initiated Phase 3 trials for MM120 ODT, a novel LSD-based treatment for generalized anxiety disorder (GAD).
The Panorama study expands on the Voyage study by including a 50-microgram dose arm to mitigate functional unblinding bias.

MindMed's MM120 Shows Promise in GAD Treatment, Prepares for Phase III Trials

MindMed's MM120, an LSD-based compound, has demonstrated statistically significant benefits over placebo in treating Generalized Anxiety Disorder (GAD).
A single dose of MM120 showed significant improvement in HAM-A scores, measuring anxiety severity, with effects lasting up to 12 weeks.

MindBio Reaches Milestone in Phase 2B Microdosing Trial for Advanced Cancer Patients

MindBio Therapeutics has dosed half of the participants in its Phase 2B trial of MB22001 for anxiety and depression in advanced cancer patients.
The trial combines MB22001 microdosing (4ug-12ug) with Meaning-Centred Psychotherapy (MCP) to improve symptoms of anxiety and depression.

Sensorium Therapeutics Advances Novel CNS Therapies Targeting Anxiety and Epilepsy

Sensorium Therapeutics presented preclinical data at Neuroscience 2024 on SENS-01, a fast-acting anxiolytic, and SENS-03, a novel treatment for drug-resistant epilepsy.
SENS-01, derived from a natural compound, demonstrated a clean safety profile and in vivo efficacy, with Phase 1 studies planned for early efficacy readouts.

MindBio's MB22001 Microdosing Formulation Shows Promise for Depression Treatment with Long-Term Stability

MindBio Therapeutics' MB22001, a microdosing formulation of LSD, has demonstrated 12-month shelf stability at room temperature, facilitating take-home use for patients.
Phase 2A trial data showed a 60% reduction in depressive symptoms and a 53% remission rate in patients with major depressive disorder following MB22001 treatment.

MindMed's MM120 Receives FDA Breakthrough Therapy Designation for Generalized Anxiety Disorder

MindMed's MM120 (lysergide d-tartrate) has been granted Breakthrough Therapy designation by the FDA for the treatment of generalized anxiety disorder (GAD).
A Phase 2b study showed a single dose of MM120 (100 μg) led to a 65% clinical response rate and a 48% clinical remission rate at 12 weeks.

MindBio Therapeutics CEO Updates on Phase 2 Clinical Trials Progress

MindBio Therapeutics Corp. CEO Justin Hanka provides an end-of-year update on the progress of two Phase 2 clinical trials using MB22001, a proprietary form of LSD for microdosing, highlighting advancements in treating Major Depressive Disorder and existential distress in late-stage cancer patients.

Reference News

[1]
MindMed to lead first LSD Phase 3 trials for anxiety - Drug Discovery and Development
drugdiscoverytrends.com · Oct 25, 2024

MindMed plans pivotal LSD study for generalized anxiety disorder, aiming to innovate stagnant anxiety treatment landscap...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy